ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 71 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2018. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,908 | -41.5% | 27,541 | -33.7% | 0.00% | – |
| Q2 2023 | $95,498 | -25.4% | 41,521 | -1.7% | 0.00% | – |
| Q1 2023 | $127,987 | +19.0% | 42,240 | -8.5% | 0.00% | – |
| Q4 2022 | $107,562 | +32.8% | 46,164 | +8.3% | 0.00% | – |
| Q3 2022 | $81,000 | -35.2% | 42,626 | -7.7% | 0.00% | – |
| Q2 2022 | $125,000 | +8.7% | 46,180 | +19.3% | 0.00% | – |
| Q1 2022 | $115,000 | -32.4% | 38,705 | -11.2% | 0.00% | – |
| Q4 2021 | $170,000 | -6.1% | 43,591 | +3.4% | 0.00% | – |
| Q3 2021 | $181,000 | -44.8% | 42,163 | -61.0% | 0.00% | – |
| Q2 2021 | $328,000 | +67.3% | 108,093 | +97.6% | 0.00% | – |
| Q1 2019 | $196,000 | -16.9% | 54,700 | -11.2% | 0.00% | -100.0% |
| Q4 2018 | $236,000 | -54.1% | 61,624 | +13.3% | 0.00% | 0.0% |
| Q3 2018 | $514,000 | +30.5% | 54,394 | +0.7% | 0.00% | 0.0% |
| Q2 2018 | $394,000 | – | 54,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |